Review clinical trials related to IgAN. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Weight of at least 40 kg [+21]
Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within... [+6]
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Mean eGFR greater than or equal to 30 mL/min/1.73m2 [+4]
Hereditary or acquired complement deficiency [+7]
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.
eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) great... [+4]
Secondary IgAN or unclear exclusion of secondary causes. [+15]
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.
A qualifying renal biopsy performed within the past 8 years; [+7]
Secondary IgA nephropathy (IgAN), as defined by the investigator. [+10]
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
Participant must be 2 to < 18 years of age at the time of signing the informed c... [+7]
Diagnosis of rapidly progressive glomerulonephritis [+13]
This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
Participant is a male or female≥18 years and≤74 years of age at the time of sign... [+8]
Participants with a history of severe allergies to drugs, food or the environmen... [+22]